***Background.*** Antibody to influenza hemagglutinin (HA) is a correlate of influenza immunity. Anti-HA antibody levels increase after infection or vaccination and then decline over time. It has been suggested that this can result in waning of vaccine effectiveness over a single influenza season. However, evidence is mixed regarding the rate of antibody decline with most studies reporting only the proportion of subjects meeting vaccine licensure criteria over time.

***Methods.*** Healthy subjects ages 18 to 49 years were enrolled in a double-blind trial and randomized to receive inactivated (IIV) or live-attenuated (LAIV) influenza vaccine or placebo. Subjects were followed over two influenza seasons (October 2005 - May 2007) without re-vaccination in the second. Serologic specimens were collected at 5 time points over follow-up. Hemagglutination inhibition (HAI) assays were performed on serologic specimens to determine HAI titers to the influenza A (H3N2) and B strains included in the 2005-06 vaccine. Rates of antibody decline among 941 subjects without evidence of influenza infection were estimated in linear models with mean log~2~ HAI titer as the outcome and time from intervention as the exposure.

***Results.*** IIV recipients achieved higher mean log~2~ HAI titers one month post-intervention than LAIV or placebo recipients (*P* \< 0.001). IIV recipients also experienced the highest rates of antibody decline; however, this appears to be driven by an association with higher peak antibody levels rather than a specific intervention effect. Despite higher rates of decline, IIV recipients maintained higher titers than LAIV or placebo recipients after 18 months (*P* \< 0.001). IIV recipients known to have been vaccinated in the 2004-05 season had higher titers prior to 2005-06 vaccination (*P* \< 0.001), but lower titers for the entire post-vaccination period than those not known to have been previously vaccinated (*P* \< 0.001).

***Conclusion.*** Moderate HAI titer decreases were observed over 18 months, suggesting a slower rate of decline than previously thought. The rate of decline increases as peak post-vaccination titer increases. Subjects vaccinated two years in a row exhibited decreased vaccine response in the second year. The impact of the persistence of HA antibody, and other immune correlates, on vaccine efficacy requires further study.
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